TuHURA Biosciences draws $1.5 million more under Parkview credit facility
The July 28, 2026 draw comes under a revolving loan agreement with Parkview Holdings One LLC that can provide up to $50 million.
TuHURA Biosciences, Inc. disclosed in an 8-K dated July 28, 2026 that it took an additional draw of $1,500,000 under its revolving credit facility with Parkview Holdings One LLC, saying the money is meant for general corporate purposes. On July 28, 2026, the Company received and borrowed an additional draw under the revolving credit facility in the amount $1,500,000 and expects to use the funds for general corporate purposes.1
The facility itself dates back to an earlier agreement. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC, as lender, which provides for a revolving credit facility that matures on April 21, 2031, with a maximum amount of loan availability of $50 million.1 The company noted that fuller terms of that agreement can be found in the loan document itself, which was filed as an exhibit to an earlier 8-K on April 22, 2026.
The filing's forward-looking statement section flagged several risks tied to the arrangement, including whether TuHURA will be able to meet the conditions needed to draw further funds or stay in compliance with the loan agreement's terms, whether the available financing will be enough to support its operations and development plans as expected, and potential conflicts of interest connected to the fact that the lender is described as an affiliate of the company's largest stockholder. Factors that could cause actual results to differ include the risk that the Company may be unable to satisfy conditions to drawdown or maintain compliance with the terms of the Loan Agreement, the risk that funds available under the Loan Agreement may be insufficient to fund the Company's operations and development programs to the extent anticipated, and potential conflicts of interest arising from the Loan Agreement with an affiliate of the Company's largest stockholder.1
The report was signed by Chief Financial Officer Dan Dearborn on July 29, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.